Pulmonary Interstitial Lymphography in Early Stage Lung Cancer

• Status: Terminated
• Trial end date: 2017-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The stereotactic body radiation therapy (SBRT) procedure is an emerging alternative to the standard treatment for early stage non-small cell lung cancer (NSCLC), typically lobectomy with lymphadenectomy. This procedure (lobectomy) does not fulfill the medical need as many patients are poor operative candidates or decline surgery.

This study assesses the feasibility of stereotactic body radiation therapy (SBRT) as a tool to produce therapeutically useful computed tomography (CT) scans, using standard water-soluble iodinated compounds as the contrast agents.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University

Criteria

INCLUSION CRITERIA

• Either:

• Established primary lung cancer/ cancer metastatic to lung, OR

• Lesion suspicious for malignancy in lung, according to the following criteria:

• Histopathologically confirmed lung cancer or cancer metastatic to lung, OR

• Plan for biopsy of suspicious lung mass based on imaging (growth on serial CT scan or nodule/mass with focal hypermetabolism on FDG-PET scan), OR

• Known metastatic cancer, with metastases to the lung based on imaging

• Age > 18 years old

• Eastern Clinical Oncology Group (ECOG) performance status 0, 1 or 2 (Appendix IV)

• No prior surgery, chemotherapy, or radiation for the current lung tumor

EXCLUSION CRITERIA

• Prior radiotherapy to thorax

• Iodine allergy

• Contraindication to receiving radiotherapy, unless undergoing surgery

• Pregnant